Efficacy and Safety of Subcutaneous Semaglutide in Overweight or Obese Adults: A Subgroup Meta-Analysis of Randomized Controlled Trials

Zhang, Rui; Hou, Qin-chuan; Li, Binghong; Deng, Lei; Yang, Yanchen; Li, Ting-xin; Yao, Xiaoqin; Yang, Liuyan; Lin, Xi-long; Liao, Yi-qian; Wang, Lin; Liu, Yuping; Tan, Jing; Wan, Zhengwei; Shuai, Ping

doi:10.2139/ssrn.4249801

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 52 weeks of treatment, semaglutide was also found to be superior regarding weight loss when compared to placebo or once‐daily liraglutide in individuals with obesity 214 . These studies add to the already established superior weight‐reducing effects of lower semaglutide doses as compared to other GLP‐1RA 213 . Regardless of the background treatment with oral antihyperglycemic drugs, semaglutide significantly reduces body weight ranging from −2.35 to −4.72 kg for 0.5 mg, and −2.96 to –6.76 kg for 1.0 mg weekly 215 .…”

Section: Introductionmentioning

confidence: 65%

“…The high dose of (2.4 mg) once‐weekly subcutaneous semaglutide paired with lifestyle modification resulted in marked weight loss compared to placebo along with improvements in cardiometabolic factors in people with obesity but without diabetes 212 . A recent systematic review and meta‐analysis of 13 RCTs on semaglutide in obese individuals reported absolute weight reduction (estimated treatment difference, ETD) of −8.97 (−10.73, −7.21) kg with a relative mean weight loss of ~10% 213 . After 52 weeks of treatment, semaglutide was also found to be superior regarding weight loss when compared to placebo or once‐daily liraglutide in individuals with obesity 214 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases

Giannakogeorgou,

Roden

2024

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThe current obesity pandemic has given rise to associated comorbidities and complications, including type 2 diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). During the last decade, certain glucagon‐like peptide 1 receptor agonists (GLP‐1RA), originally developed as antihyperglycemic drugs, also demonstrated efficacy for weight loss.AimsTo review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications.MethodsWe performed an extensive literature research to describe the effects of lifestyle modification, first‐generation anti‐obesity drugs, and GLP‐1RA on weight loss in humans with obesity, type 2 diabetes and MASLD.ResultsUntil recently, treatment of obesity has been limited to lifestyle modification, which offer moderate degree and sustainability of weight loss. The few approved first‐generation anti‐obesity drugs are either limited to short term use or to certain forms of obesity. Some GLP‐1RA significantly decrease caloric intake and body weight. Liraglutide and semaglutide have therefore been approved for treating people with obesity. They also lead to a reduction of hepatic fat content and inflammation in people with biopsy‐confirmed MASLD. Possible limitations comprise adverse effects, treatment adherence and persistence.ConclusionCertain GLP‐1RA are superior to lifestyle modification and first‐generation anti‐obesity drugs in inducing weight loss. They have therefore markedly changed the portfolio of obesity treatment with additional beneficial effects on steatotic liver disease.

show abstract

Section: Introductionmentioning

confidence: 65%